HUMACYTE INC. news, videos and press releases
For more news please use our advanced search feature.
HUMACYTE INC. - More news...
HUMACYTE INC. - More news...
- Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
- Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
- Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
- Humacyte, Inc. Announces Proposed Public Offering of Common Stock
- Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
- Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
- Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
- Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
- Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
- Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
- Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
- Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
- Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
- Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
- Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
- Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
- Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
- Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
- Humacyte Third Quarter 2024 Financial Results and Business Update
- Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024
- Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
- Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
- Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
- Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
- Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
- Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
- Humacyte to Participate at Upcoming Investor Conferences in September
- Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
- Humacyte Second Quarter 2024 Financial Results and Business Update
- Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
